Serial whole-body cryotherapy in fibromyalgia is effective and alters cytokine profiles
Tóm tắt
Whole-body cryotherapy (WBC) has shown to be beneficial in the treatment of fibromyalgia (FM). There is cumulative evidence that cytokines play a crucial role in FM. It’s unknown whether clinical effects of WBC can be demonstrated at the molecular level and how long the effects last.
We compared effects of serial WBC (6 sessions (− 130 °C in 6 weeks) in FM patients and healthy controls (HC). Primary outcome was the change in pain level (visual analogue scale 0–100 mm) after 6 sessions. Secondary outcomes were a change in disease activity (revised Fibromyalgia Impact Questionnaire) and pain after 3 sessions and 3 months after discontinued therapy and in cytokine levels (interleukin (IL-)1, IL-6, tumor necrosis factor α (TNF-α) and IL-10). The patients’ opinions on the satisfaction, effectiveness and significance of WBC were evaluated.
Twenty-three FM patients and 30 HC were enrolled. WBC resulted in a significant reduction in pain and disease activity after 3 and 6 sessions. No clinical benefit could be measured 3 months after discontinued treatment. Overall, probands were satisfied with WBC and considered WBC to be important and effective. FM patients had significantly different levels of IL-1, IL-6, TNF-α and IL-10 at each reading point compared to HC. Levels of IL-1, IL-6 and IL-10 were significantly altered over time in FM patients. Compared to HC FM patients showed a significantly different response of IL1, − 6 and − 10 to WBC.
Serial WBC is a fast acting and effective treatment for FM. Proven effects of WBC may be explained by changes in cytokines.
Từ khóa
Tài liệu tham khảo
Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600–10. https://doi.org/10.1002/acr.20140.
Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19–28. https://doi.org/10.1002/art.1780380104.
Wolfe F, Smythe HA, Yunus MB, et al. The american college of rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum. 1990;33:160–72. https://doi.org/10.1002/art.1780330203.
Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013;17:356. https://doi.org/10.1007/s11916-013-0356-5.
Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther. 2009;11:117.
Knight T, Schaefer C, Chandran A, et al. Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States. Clin Outcomes Res. 2013;5:171–80. https://doi.org/10.2147/CEOR.S41111.
Bradley LA. Pathophysiology of fibromyalgia. Am J Med. 2009;122:S22–30. https://doi.org/10.1016/j.amjmed.2009.09.008.
Häuser W, Ablin J, Fitzcharles M-A, et al. Fibromyalgia. Nat Rev Dis Primers. 2015;1:15022. https://doi.org/10.1038/nrdp.2015.22.
Crofford LJ, Pillemer SR, Kalogeras KT, et al. Hypothalamic–pituitary–adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37:1583–92. https://doi.org/10.1002/art.1780371105.
Tak LM, Cleare AJ, Ormel J, et al. Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. Biol Psychol. 2011;87:183–94.
Rodriguez-Pintó I, Agmon-Levin N, Howard A, Shoenfeld Y. Fibromyalgia and cytokines. Immunol Lett. 2014;161:200–3. https://doi.org/10.1016/j.imlet.2014.01.009.
Littlejohn G, Guymer E. Neurogenic inflammation in fibromyalgia. Semin Immunopathol. 2018;40:291–300.
Ahrens C, Schiltenwolf M, Wang H. Cytokines in psychoneuroendocrine immunological context of nonspecific musculoskeletal pain. Schmerz. 2012;26:383–8. https://doi.org/10.1007/s00482-012-1153-5.
Kiguchi N, Kobayashi Y, Kishioka S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol. 2012;12:55–61.
Wolf G, Gabay E, Tal M, et al. Genetic impairment of interleukin-1 signaling attenuates neuropathic pain, autotomy, and spontaneous ectopic neuronal activity, following nerve injury in mice. Pain. 2006;120:315–24. https://doi.org/10.1016/j.pain.2005.11.011.
Mourot L, Cluzeau C, Regnard J. Hyperbaric gaseous Cryotherapy: effects on skin temperature and systemic vasoconstriction. Arch Phys Med Rehabil. 2007;88:1339–43. https://doi.org/10.1016/j.apmr.2007.06.771.
Algafly AA, George KP. The effect of cryotherapy on nerve conduction velocity, pain threshold and pain tolerance. Br J Sports Med. 2007;41:365–9. https://doi.org/10.1136/bjsm.2006.031237.
Rose C, Edwards KM, Siegler J, et al. Whole-body Cryotherapy as a recovery technique after exercise: a review of the literature. Int J Sports Med. 2017;38:1049–60. https://doi.org/10.1055/s-0043-114861.
Lange U, Uhlemann C, Müller-Ladner U. Serial whole-body cryotherapy in the criostream for inflammatory rheumatic diseases. A pilot study. Med Klin. 2008;103:383–8. https://doi.org/10.1007/s00063-008-1056-5.
Bouzigon R, Grappe F, Ravier G, Dugue B. Whole- and partial-body cryostimulation/cryotherapy: current technologies and practical applications. J Therm Biol. 2016;61:67–81.
Stanek A, Cholewka A, Gadula J, et al. Can whole-body cryotherapy with subsequent kinesiotherapy procedures in closed type cryogenic chamber improve BASDAI, BASFI, and some spine mobility parameters and decrease pain intensity in patients with ankylosing spondylitis? Biomed Res Int. 2015;2015:404259. https://doi.org/10.1155/2015/404259.
Lubkowska A, Szygula Z, Klimek AJ, Torii M. Do sessions of cryostimulation have influence on white blood cell count, level of IL6 and total oxidative and antioxidative status in healthy men? Eur J Appl Physiol. 2010;109(1):67–72.
Lubkowska A, Szyguła Z, Chlubek D, Banfi G. The effect of prolonged whole-body cryostimulation treatment with different amounts of sessions on chosen pro-and anti-inflammatory cytokines levels in healthy men. Scand J Clin Lab Invest. 2011;71:419–25. https://doi.org/10.3109/00365513.2011.580859.
Lange U, Dischereit G. Effects of different iterative whole-body hyperthermia on pain and cytokines in rheumatic diseases: a current review. Aktuelle Rheumatol. 2018. https://doi.org/10.1055/s-0044-101543.
Lange U, Müller-Ladner U, Dischereit G. Rheumatic diseases and molecular physical medicine – new aspects. Phys Medizin, Rehabil Kurortmedizin. 2017;27:205–10. https://doi.org/10.1055/s-0043-113045.
Bettoni L, Bonomi FG, Zani V, et al. Effects of 15 consecutive cryotherapy sessions on the clinical output of fibromyalgic patients. Clin Rheumatol. 2013;32:1337–45. https://doi.org/10.1007/s10067-013-2280-9.
Rivera J, Tercero MJ, Salas JS, et al. The effect of cryotherapy on fibromyalgia: a randomised clinical trial carried out in a cryosauna cabin. Rheumatol Int. 2018;38:2243–50. https://doi.org/10.1007/s00296-018-4176-0.
Vitenet M, Tubez F, Marreiro A, et al. Effect of whole body cryotherapy interventions on health-related quality of life in fibromyalgia patients: a randomized controlled trial. Complement Ther Med. 2018;36:6–8. https://doi.org/10.1016/j.ctim.2017.10.011.
Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46:319–29. https://doi.org/10.1016/j.semarthrit.2016.08.012.
Bijur PE, Silver W, Gallagher EJ. Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med. 2001;8:1153–7. https://doi.org/10.1111/j.1553-2712.2001.tb01132.x.
Casale R, Rainoldi A. Fatigue and fibromyalgia syndrome: clinical and neurophysiologic pattern. Best Pract Res Clin Rheumatol. 2011;25:241–7. https://doi.org/10.1016/j.berh.2011.01.016.
Mease PJ, Spaeth M, Clauw DJ, et al. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res (Hoboken). 2011;63:821–6. https://doi.org/10.1002/acr.20449.
Bennett RM, Friend R, Jones KD, et al. The revised fibromyalgia impact questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11:R120. https://doi.org/10.1186/ar2783.
Bennett RM, Bushmakin AG, Cappelleri JC, et al. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol. 2009;36:1304–11. https://doi.org/10.3899/jrheum.081090.
Üçeyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord. 2011;12:245.
Bidonde J, Busch AJ, Schachter CL, et al. Aerobic exercise training for adults with fibromyalgia. Cochrane Database Syst Rev. 2017. https://doi.org/10.1002/14651858.CD012700.
Palstam A, Mannerkorpi K. Work ability in fibromyalgia: an update in the 21st century. Curr Rheumatol Rev. 2017;13:180–7. https://doi.org/10.2174/1573397113666170502152955.
Staud R. Abnormal pain modulation in patients with spatially distributed chronic pain: fibromyalgia. Rheum Dis Clin North Am. 2009;35:263–74.
Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333–43. https://doi.org/10.1002/art.10225.
Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum. 2003;48:1420–9. https://doi.org/10.1002/art.10893.
Malcangio M, Bowery NG, Flower RJ, Perretti M. Effect of interleukin-1β on the release of substance P from rat isolated spinal cord. Eur J Pharmacol. 1996;299:113–8. https://doi.org/10.1016/0014-2999(95)00845-4.
Janik JE, Miller LL, Longo DL, et al. Phase II trial of interleukin 1α and indomethacin in treatment of metastatic melanoma. J Natl Cancer Inst. 1996;88:44–9. https://doi.org/10.1093/jnci/88.1.44.
Wallace DJ, Linker-Israeli M, Hallegua D, et al. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology. 2001;40:743–9. https://doi.org/10.1093/rheumatology/40.7.743.
Ernberg M, Christidis N, Ghafouri B, et al. Plasma cytokine levels in fibromyalgia and their response to 15 weeks of progressive resistance exercise or relaxation therapy. Mediators Inflamm. 2018;2018:3985154. https://doi.org/10.1155/2018/3985154.